IL308112B2 - A dominant active YAP gene, which activates HIPPO, induces chromatin accessibility and myocardial cell renewal - Google Patents

A dominant active YAP gene, which activates HIPPO, induces chromatin accessibility and myocardial cell renewal

Info

Publication number
IL308112B2
IL308112B2 IL308112A IL30811223A IL308112B2 IL 308112 B2 IL308112 B2 IL 308112B2 IL 308112 A IL308112 A IL 308112A IL 30811223 A IL30811223 A IL 30811223A IL 308112 B2 IL308112 B2 IL 308112B2
Authority
IL
Israel
Prior art keywords
amino acid
acid substitutions
mutated variant
yap
yap protein
Prior art date
Application number
IL308112A
Other languages
English (en)
Hebrew (he)
Other versions
IL308112A (en
IL308112B1 (en
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of IL308112A publication Critical patent/IL308112A/en
Publication of IL308112B1 publication Critical patent/IL308112B1/en
Publication of IL308112B2 publication Critical patent/IL308112B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
IL308112A 2017-03-14 2018-03-14 A dominant active YAP gene, which activates HIPPO, induces chromatin accessibility and myocardial cell renewal IL308112B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471204P 2017-03-14 2017-03-14
PCT/US2018/022496 WO2018170172A1 (en) 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal

Publications (3)

Publication Number Publication Date
IL308112A IL308112A (en) 2023-12-01
IL308112B1 IL308112B1 (en) 2024-09-01
IL308112B2 true IL308112B2 (en) 2025-01-01

Family

ID=63523973

Family Applications (2)

Application Number Title Priority Date Filing Date
IL308112A IL308112B2 (en) 2017-03-14 2018-03-14 A dominant active YAP gene, which activates HIPPO, induces chromatin accessibility and myocardial cell renewal
IL269187A IL269187B2 (en) 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL269187A IL269187B2 (en) 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal

Country Status (10)

Country Link
US (3) US11484553B2 (enExample)
EP (1) EP3595642A4 (enExample)
JP (3) JP2020513810A (enExample)
CN (2) CN116003564A (enExample)
AU (2) AU2018234632B2 (enExample)
BR (1) BR112019018912A2 (enExample)
CA (1) CA3056231A1 (enExample)
IL (2) IL308112B2 (enExample)
MX (2) MX2019010986A (enExample)
WO (1) WO2018170172A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634495A4 (en) * 2017-06-01 2021-02-24 Baylor College of Medicine Dystrophin glycoprotein complex sequesters yap to inhibit cardiomyocyte proliferation
US11179479B2 (en) 2018-01-05 2021-11-23 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
WO2021119030A1 (en) * 2019-12-09 2021-06-17 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
US20210324412A1 (en) * 2020-04-15 2021-10-21 University Of Southern California Activation of yap signaling for sensory receptor regeneration
CN111778281B (zh) * 2020-07-17 2021-04-23 四川省人民医院 一种视网膜双极细胞病变模型的构建方法及其应用
US20230193267A1 (en) * 2021-10-19 2023-06-22 Animatus Biosciences, Inc. Cardiac cell proliferation by administering inhibitors of sav1, nf2, mob1 and/or mutant srf
WO2024168269A1 (en) * 2023-02-10 2024-08-15 Baylor College Of Medicine Use of mutant yap for improving cardiac function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
TW563139B (en) 2000-11-30 2003-11-21 Nec Tokin Corp Magnetic core including magnet for magnetic bias and inductor component using the same
US8140593B2 (en) * 2008-05-15 2012-03-20 Microsoft Corporation Data viewer management
KR101057116B1 (ko) 2008-06-17 2011-08-16 한국과학기술원 포유류에서의 분화 조절제 및 분화 조절 방법
AU2013243952A1 (en) * 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10772974B2 (en) * 2013-11-18 2020-09-15 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
CN103705505A (zh) * 2013-12-19 2014-04-09 清华大学深圳研究生院 辛伐他汀的新用途
US20160361340A1 (en) * 2014-02-11 2016-12-15 Inetitut Pasteur Treatment of cardiac diseases with modulators of the hippo pathway
US20170246215A1 (en) * 2014-09-16 2017-08-31 Albert Einstein College Of Medicine, Inc. Repopulation of organs and tissues using a yap-ert2 fusion protein
GB201819659D0 (en) * 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIN, ZHIQIANG, ET AL., CARDIAC-SPECIFIC YAP ACTIVATION IMPROVES CARDIAC FUNCTION AND SURVIVAL IN AN EXPERIMENTAL MURINE MI MODEL, 31 December 2014 (2014-12-31) *
VON GISE, ALEXANDER, ET AL., YAP1, THE NUCLEAR TARGET OF HIPPO SIGNALING, STIMULATES HEART GROWTH THROUGH CARDIOMYOCYTE PROLIFERATION BUT NOT HYPERTROPHY, 31 December 2012 (2012-12-31) *
ZHAO, BIN, ET AL., A COORDINATED PHOSPHORYLATION BY LATS AND CK1 REGULATES YAP STABILITY THROUGH SCF?-TRCP, 31 December 2010 (2010-12-31) *
ZHAO, BIN, ET AL., BOTH TEAD-BINDING AND WW DOMAINS ARE REQUIRED FOR THE GROWTH STIMULATION AND ONCOGENIC TRANSFORMATION ACTIVITY OF YES-ASSOCIATED PROTEIN, 31 December 2009 (2009-12-31) *

Also Published As

Publication number Publication date
BR112019018912A2 (pt) 2020-04-14
CN110520112A (zh) 2019-11-29
US20230063735A1 (en) 2023-03-02
IL308112A (en) 2023-12-01
JP2024073571A (ja) 2024-05-29
IL269187B2 (en) 2024-04-01
US20250073276A1 (en) 2025-03-06
WO2018170172A1 (en) 2018-09-20
EP3595642A4 (en) 2021-05-26
MX2022011881A (es) 2022-11-09
IL269187A (en) 2019-11-28
CA3056231A1 (en) 2018-09-20
US20200016212A1 (en) 2020-01-16
US12138284B2 (en) 2024-11-12
AU2018234632B2 (en) 2024-06-13
CN116003564A (zh) 2023-04-25
JP7461071B2 (ja) 2024-04-03
US11484553B2 (en) 2022-11-01
AU2024219497B2 (en) 2025-08-14
AU2024219497A1 (en) 2024-10-03
JP2020513810A (ja) 2020-05-21
IL308112B1 (en) 2024-09-01
JP2022164658A (ja) 2022-10-27
AU2018234632A1 (en) 2019-10-03
IL269187B1 (en) 2023-12-01
MX2019010986A (es) 2020-02-05
EP3595642A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
IL308112B2 (en) A dominant active YAP gene, which activates HIPPO, induces chromatin accessibility and myocardial cell renewal
Beniash et al. The effect of recombinant mouse amelogenins on the formation and organization of hydroxyapatite crystals in vitro
CN104487081B (zh) 用于预防或治疗恶病质的组合物
RU2006109011A (ru) Пептиды, способные связываться с трансформирующим фактором роста в1 (tgf-в1)
EP1778842B8 (en) Compositions and methods of use for mgd-csf in disease treatment
US9962465B2 (en) Amelogenin-chitosan hydrogel for dentin hypersensitivity
MX2008009493A (es) Peptido novedoso y uso del mismo.
JP2020513810A5 (enExample)
US20080015150A1 (en) Peptides and Derivatives Thereof Showing Cell Attachment, Spreading and Detachment Activity
WO2019094938A3 (en) Methods and compositions for the treatment of wounds
WO2014050908A1 (ja) ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物
AU2001220262A1 (en) Peptides and derivatives thereof showing cell attachment, spreading and detachment activity
JP2002345468A5 (enExample)
JP2017530088A5 (enExample)
JPH03297388A (ja) 新規なｔｎｆ変異体、その製造法及びそれを有効成分とする抗腫瘍剤
KR20130110606A (ko) 줄기세포의 연골 분화 유도 활성을 가지는 폴리펩타이드
KR20150080746A (ko) 페리오스틴 단백질 또는 이의 단편을 유효성분으로 포함하는 허혈성 질환의 예방 또는 치료용 조성물
US5973115A (en) Method for potentiating and inhibiting insulin-like growth factor activity
EP4527469A3 (en) Biomimetic peptides derived from biological source and their uses in retarding aging and improving skin
KR20140095295A (ko) 재조합 상아질 인산단백질을 포함하는 치수 세포의 부착 또는 증식 촉진용 조성물
RU2012106506A (ru) Вакцина
KR101559884B1 (ko) 재조합 상아질 인산단백질을 포함하는 치수 세포의 부착 또는 증식 촉진용 조성물
ZA202401136B (en) Means and methods for the treatment of calcium crystal deposition diseases
WO2025133158A3 (en) Method to produce phosphorylated milk proteins in microbes
WO2003087318A3 (en) Truncated 24 kda basic fibroblast growth factor